170 reports of this reaction
1.5% of all OZANIMOD HYDROCHLORIDE reports
#14 most reported adverse reaction
MULTIPLE SCLEROSIS is the #14 most commonly reported adverse reaction for OZANIMOD HYDROCHLORIDE, manufactured by Celgene Corporation. There are 170 FDA adverse event reports linking OZANIMOD HYDROCHLORIDE to MULTIPLE SCLEROSIS. This represents approximately 1.5% of all 11,558 adverse event reports for this drug.
Patients taking OZANIMOD HYDROCHLORIDE who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is a less commonly reported adverse event for OZANIMOD HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to multiple sclerosis, the following adverse reactions have been reported for OZANIMOD HYDROCHLORIDE:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 170 FDA reports for OZANIMOD HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 1.5% of all adverse event reports for OZANIMOD HYDROCHLORIDE, making it a notable side effect.
If you experience multiple sclerosis while taking OZANIMOD HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.